Delving into the Latest Updates on Recombinant Hepatitis B Vaccine (Hansenula, CpG and Aluminum Adjuvant)(Huapu Shijiazhuang) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine, Genetically engineered subunit vaccine

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious DiseasesDigestive System Disorders

Active Indication

Hepatitis B

Inactive Indication-

Originator Organization

Huapu Shijiazhuang Pharmaceutical Co., Ltd.

Active Organization

Huanke (Hebei) Biotechnology Co., Ltd.Huapu Shijiazhuang Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Primary objective: To evaluate the safety and tolerability of investigational vaccines with different CpG adjuvant concentrations administered in a 3-dose immunization schedule at 0, 1, and 6 months in individuals aged 18 years and older. Secondary objective: To evaluate the preliminary immunogenicity of investigational vaccines with different CpG adjuvant concentrations administered in a 3-dose immunization schedule at 0, 1, and 6 months in individuals aged 18 years and older.

Start Date-

Sponsor / Collaborator

Huapu Shijiazhuang Pharmaceutical Co., Ltd.

[+1]

100 Clinical Results associated with Recombinant Hepatitis B Vaccine (Hansenula, CpG and Aluminum Adjuvant)(Huapu Shijiazhuang)

Login to view more data

100 Translational Medicine associated with Recombinant Hepatitis B Vaccine (Hansenula, CpG and Aluminum Adjuvant)(Huapu Shijiazhuang)

Login to view more data

100 Patents (Medical) associated with Recombinant Hepatitis B Vaccine (Hansenula, CpG and Aluminum Adjuvant)(Huapu Shijiazhuang)

Login to view more data

100 Deals associated with Recombinant Hepatitis B Vaccine (Hansenula, CpG and Aluminum Adjuvant)(Huapu Shijiazhuang)

Login to view more data